查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1868263

Dravet症候群市場按藥物類別、最終用戶、通路、給藥途徑和患者年齡層分類 - 全球預測 2025-2032

Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route Of Administration, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Dravet 症候群市場規模將達到 14.5989 億美元，複合年成長率為 8.97%。

關鍵市場統計數據
基準年 2024 7.3404億美元
預計年份：2025年 8.8億美元
預測年份 2032 1,459,890,000 美元
複合年成長率 (%) 8.97%

這是一份全面且具有臨床依據的Dravet症候群概述，重點介紹了診斷技術的進展、治療的複雜性以及不斷變化的醫療保健服務需求。

Dravet症候群是一種罕見的嚴重癲癇性腦病變，發病於嬰兒期，其特徵是長期、難治性癲癇發作和進行性神經發育障礙。臨床管理複雜且涉及多學科，需要神經內科、急診科、癲癇專科中心和家庭看護者之間的密切協調。儘管近年來透過早期基因檢測提高了診斷準確性，並且人們對該疾病的表現型多樣性認知不斷提高，但許多患者仍然面臨嚴重的癲癇發作負擔和顯著的合併症，導致醫療需求未得到滿足。

確定臨床、監管和數位因素的融合，這些融合將從根本上改變德拉韋症候群的治療路徑、治療機會和相關人員的優先事項。

Dravet症候群的治療模式正受到多種變革因素的影響而轉變，這些因素正在重塑臨床護理、研究重點和商業策略。在臨床層面，早期基因診斷和以表現型為基礎的治療選擇使得更個人化的治療方案成為可能，而日益成熟的癲癇專科網路則集中了專業知識，並改善了長期照護的協調性。同時，藥理學的進步正在豐富治療選擇，並重新激發人們對靶向離子通道功能、GABA能調節和神經調節通路的不同藥物類別的興趣。

了解不斷變化的美國關稅政策對供應鏈、籌資策略以及治療德拉韋症候群藥物取得途徑的累積營運和商業影響。

2025年，美國關稅趨勢為德拉韋症候群治療領域的製造商、經銷商和供應商的營運帶來了新的複雜性。影響進口活性藥物原料藥、某些醫療設備和包裝組件的關稅增加了上游工程投入成本，促使許多企業重新評估其供應鏈的韌性。擁有全球製造地的公司被迫評估商品的總到岸成本，並考慮將關鍵生產過程流程轉移到國內或近岸，以降低貿易政策波動帶來的風險。

透過整合藥物類別、臨床環境、通路、給藥途徑和特定年齡層的臨床需求等因素，進行深度細分，從而指南策略規劃。

細分市場分析揭示了不同藥物類別、終端使用者、分銷管道、給藥途徑和患者群體在臨床和商業性動態方面存在顯著差異。在藥物類別細分中，基於大麻素的藥物持續受到關注，其治療益處主要集中在大麻二酚 (CBD) 和四氫大麻酚 (THC) 這兩種亞成分上。同時，包括Clobazam、Diazepam和曲普尼硫醇在內的 GABA 調節劑仍然是核心輔助性治療。托吡酯和丙戊酸鈉等鈉通道阻斷劑對某些類型的癲癇發作仍然有效，這些藥物的相對安全性和耐受性會影響處方醫生的選擇和聯合治療策略。

區域臨床和商業性洞察反映了美洲、歐洲、中東和非洲以及亞太地區的准入實踐、監管差異和醫療保健基礎設施。

區域趨勢對德拉韋症候群治療的臨床實踐、法規環境和商業性機會有顯著影響。在美洲，相關人員受益於成熟的專科醫療網路、先進的基因診斷基礎設施以及不斷發展的支付模式，這些都提高了對具有臨床和功能改善意義的證據的接受度。然而，醫療服務取得仍面臨挑戰，尤其是在農村和資源匱乏的社區，這些地區的癲癇專科中心稀缺，遠端醫療的普及程度也因支付方政策而異。

策略企業格局分析揭示了大型製藥企業、生物技術創新者、學術研究機構和服務供應商之間的整合能力將如何決定它們的競爭地位。

Dravet症候群的生態系統是一個由眾多互補參與者組成的複雜體系，其中包括成熟的製藥公司、專業生物技術公司、學術研究機構、契約製造生產商和專科藥房。現有企業擁有後期研發和大規模生產能力，以及支援與複雜的支付方談判和廣泛分銷網路的商業基礎設施。專業生物技術公司則透過標靶作用機制和新型製劑提供創新，推動早期臨床試驗，並利用策略夥伴關係擴大治療方法規模。

針對德拉韋症候群利害關係人的獨特需求，針對產品開發、供應鏈最佳化和支付方參與，提出切實可行且影響深遠的建議。

行業領導者應採取務實、以證據為導向的行動，將科學進步轉化為永續的患者獲益和商業性成功。首先，應優先與監管機構和支付方進行早期和持續的溝通，使證據生成與報銷要求相符，並製定能夠滿足兒童安全性和有效性終點的適應性開發計劃。其次，應投資於診斷基礎設施和基因檢測夥伴關係，以加速早期精準診斷，從而改善臨床實驗參加者的招募和真實世界治療標靶的識別。

採用透明的混合方法調查方法，結合臨床證據審查、專家訪談和案例研究分析，以得出可操作且檢驗的研究結果。

本分析的調查方法結合了嚴謹的證據綜合和有針對性的相關利益者參與，以確保其相關性和可信度。主要資料來源包括對同行評審的臨床文獻、監管指導文件和臨床試驗註冊資料的系統性回顧，以了解治療機制、安全性特徵和研究設計。次要資料來源包括公開的政策和支付方文件、技術白皮書和實踐指南，以闡明准入途徑和臨床應用趨勢。此外，也對神經科、癲癇學家、專科藥劑師和衛生經濟學專家進行了專家訪談，以檢驗解釋性發現並提取文獻中未必總是顯而易見的實際操作考量。

前瞻性結論整合了臨床進展、營運要務以及改善Dravet症候群患者照護和就醫途徑所需的協作策略。

總之，應對德拉韋症候群複雜的臨床和商業性挑戰需要診斷、治療和醫療服務取得方面的協調努力。基因診斷技術的進步和治療方法的多樣化為改善癲癇控制和發育結果創造了新的機遇，但要實現這些益處，需要嚴謹的循證策略、穩健的供應鏈以及與支付共用的價值認知。儘管醫療服務模式向遠端醫療和以專家為中心的模式轉變為擴大醫療服務取得鋪平了道路，但仍存在一些差距，需要在地方和區域層面採取有針對性的干涉措施。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大針對Dravet症候群患者SCN1A突變的基因治療產品線
  • 大麻二酚製劑在Dravet症候群輔助癲癇治療的應用日益廣泛
  • 增加對精準醫療舉措的投入，以治療兒童癲癇性腦病變
  • 在整合真實世界數據以評估Dravet症候群長期治療效果方面取得進展
  • 新型反義寡核苷酸的出現，旨在調節缺陷鈉通道基因表現。
  • 開發一種基於人工智慧的家用癲癇監測設備，可對德拉韋症候群進行即時干預。
  • 透過製藥公司和生技公司之間的合作，加速罕見癲癇疾病的臨床試驗

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. Dravet症候群藥物市場

  • 大麻素
    • CBD
    • THC
  • GABA調變器
    • Clobazam
    • Diazepam
    • 鏈戊硫醇
  • 鈉通道阻斷劑
    • 托吡酯
    • 丙戊酸

9. 按最終用戶分類的德拉韋氏症候群市場

  • 居家照護
  • 醫院
  • 癲癇專科中心

第10章 Dravet症候群市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第11章 德拉韋氏症候群藥物市場（依給藥途徑分類）

  • 注射
  • 鼻腔
  • 口服
  • 口腔黏膜給藥
  • 經皮

第12章：依患者年齡層分類的德拉韋症候群市場

  • 青春期
  • 成人
  • 兒童
  • 嬰兒

第13章 德拉韋氏症候群市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 德拉韋氏症候群市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國德拉韋氏症候群市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Jazz Pharmaceuticals plc
    • UCB SA
    • Marinus Pharmaceuticals, Inc.
    • Stoke Therapeutics, Inc.
    • Zogenix, Inc.
    • Biogen Inc.
    • Ionis Pharmaceuticals, Inc.
    • Xenon Pharmaceuticals Inc.
    • Ovid Therapeutics, Inc.
    • Zynerba Pharmaceuticals, Inc.
Product Code: MRR-4D00F1312C81

The Dravet Syndrome Market is projected to grow by USD 1,459.89 million at a CAGR of 8.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 734.04 million
Estimated Year [2025] USD 800.08 million
Forecast Year [2032] USD 1,459.89 million
CAGR (%) 8.97%

A comprehensive and clinically grounded introduction to Dravet syndrome emphasizing diagnostic advances, therapeutic complexity, and evolving care delivery imperatives

Dravet syndrome represents a rare, severe epileptic encephalopathy with onset in infancy, characterized by prolonged, treatment-resistant seizures and progressive neurodevelopmental impairment. Clinical management is complex and multidisciplinary, requiring careful coordination between neurology, emergency medicine, specialty epilepsy centers, and home-based caregivers. Recent years have seen advances in diagnostic precision through earlier genetic testing and improved recognition of the condition's phenotypic heterogeneity, yet many patients continue to experience high seizure burden and profound comorbidities that drive unmet clinical needs.

This introduction frames the landscape in terms of evolving therapeutic modalities, care delivery shifts, and commercial implications. It emphasizes the interplay between novel pharmacologic strategies targeting specific pathophysiologic mechanisms, supportive and rescue interventions for acute events, and the critical role of specialized care settings. The narrative also highlights how payer policies, distribution pathways, and patient age segmentation shape access and adherence. By situating Dravet syndrome within contemporary clinical practice and policy trends, the section primes stakeholders to evaluate opportunities across drug classes, routes of administration, and care delivery innovations while remaining attuned to the ethical and regulatory complexities that accompany treatments for pediatric populations.

Identifying the convergent clinical, regulatory, and digital forces that are fundamentally transforming treatment pathways, therapy access, and stakeholder priorities in Dravet syndrome

The landscape for Dravet syndrome is shifting along multiple transformative vectors that are reshaping clinical care, research priorities, and commercial strategies. At the clinical level, earlier genetic diagnosis and phenotype-driven treatment selection are enabling more personalized therapeutic approaches, while the maturation of epilepsy specialty networks is concentrating expertise and improving longitudinal care coordination. Concurrently, advances in pharmacology have diversified the treatment palette, bringing renewed attention to distinct drug classes that target ion channel function, GABAergic modulation, and neuromodulatory pathways.

On the commercial front, digital health tools and telemedicine have expanded care touchpoints and facilitated remote monitoring, thereby altering traditional patterns of utilization across hospitals, specialty centers, and home care. Distribution channel innovation-spanning hospital pharmacies to specialty and online pharmacies-has reconfigured access pathways for high-cost therapies and acute rescue medications. At the same time, regulatory and reimbursement environments are evolving to address the specific needs of rare pediatric disorders, prompting manufacturers to prioritize evidence generation strategies that demonstrate both clinical benefit and real-world impact. Together, these shifts present a new set of opportunities and constraints for stakeholders seeking to advance therapeutic options while ensuring equitable access and sustainable reimbursement.

Understanding the cumulative operational and commercial consequences of evolving United States tariff policies on supply chains, procurement strategies, and access to Dravet syndrome therapies

In 2025, United States tariff dynamics have introduced an additional layer of operational complexity for manufacturers, distributors, and providers engaged in the Dravet syndrome ecosystem. Tariffs that affect imported active pharmaceutical ingredients, certain medical devices, and packaging components have increased upstream input costs and prompted many organizations to re-evaluate supply chain resilience. Firms with global manufacturing footprints have been compelled to assess the total landed cost of goods and to consider options for onshoring or nearshoring critical production steps to mitigate exposure to trade policy volatility.

These supply-side pressures interact with distribution practices in meaningful ways. Specialty pharmacies and hospital procurement groups are adapting contracting strategies to absorb or pass through incremental costs, with implications for inventory management, formulary placement negotiations, and patient out-of-pocket liability. Payers and integrated delivery networks are increasingly scrutinizing cost drivers and may demand enhanced pharmacoeconomic evidence or value-based contracting arrangements to justify coverage of higher-cost therapies. Additionally, tariff-induced changes in component sourcing have accelerated interest in manufacturing partnerships and consolidation among smaller biotechs that lack vertical integration. Overall, the cumulative effect of tariffs is to increase the importance of proactive supply chain planning, transparent cost modeling, and strategic engagement with procurement stakeholders to preserve access and commercial viability.

Deep segmentation-driven insights that synthesize drug class, care setting, distribution pathways, administration routes, and age-group specific clinical imperatives to guide strategy

Segmentation insights reveal differentiated clinical and commercial dynamics across drug classes, end users, distribution channels, routes of administration, and patient age groups. Within drug class segmentation, cannabinoids have garnered sustained interest with therapeutic activity concentrated in cannabidiol and tetrahydrocannabinol subcomponents, while GABA modulators encompass agents such as clobazam, diazepam, and stiripentol that remain central to adjunctive and rescue strategies. Sodium channel blockers, including agents like topiramate and valproate, continue to be relevant for certain seizure phenotypes, and the comparative safety and tolerability profiles of these classes inform prescriber choice and polytherapy strategies.

End user segmentation underscores distinct care delivery pathways: home care settings are increasingly important for long-term maintenance regimens and rescue medication administration, hospitals remain the locus for acute management and complex diagnostics, and specialty epilepsy centers provide concentrated expertise for refractory cases and surgical evaluations. Distribution channel segmentation shapes access modalities and patient experience, as hospital pharmacies, online pharmacies, retail pharmacies, and specialty pharmacies each present different operational and reimbursement interfaces that can affect initiation and continuity of therapy. Route of administration is another critical axis of differentiation; injectable and nasal routes are prioritized for rapid rescue intervention, oral and oromucosal forms support chronic management, and transdermal approaches are being explored for adherence and tolerability benefits. Patient age group segmentation highlights the spectrum of clinical needs across adolescents, adults, children, and infants, with infants and young children requiring tailored dosing, formulation considerations, and heightened safety monitoring. Integrating these segmentation lenses is essential for designing clinical development programs, market access strategies, and patient support services that align with real-world care pathways.

Regionally nuanced clinical and commercial insights that map access realities, regulatory differences, and care infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on clinical practice, regulatory environments, and commercial opportunity for therapies addressing Dravet syndrome. In the Americas, stakeholders benefit from established specialty care networks, advanced genetic diagnostics infrastructure, and evolving payer models that are increasingly receptive to evidence demonstrating meaningful clinical and functional gains. Access challenges persist, however, particularly in rural and under-resourced communities where specialty epilepsy centers are scarce and telehealth adoption varies by payer policy.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer systems that require tailored market entry strategies; centralized approvals and national reimbursement negotiations can lead to divergent timelines and formulary outcomes across countries. Countries with strong rare disease programs and coordinated registries show faster uptake of innovative therapies, while others face infrastructure and funding constraints that limit access. Asia-Pacific is characterized by rapid adoption of diagnostic technologies in some markets and variable reimbursement pathways across others. Local manufacturing and procurement policies, as well as differing regulatory expectations for pediatric data, shape clinical adoption and commercial pathways. Across all regions, meaningful engagement with patient advocacy groups, investment in provider education, and alignment with local clinical guidelines remain critical to improving diagnosis, treatment initiation, and long-term management outcomes.

Strategic company landscape analysis highlighting how integrated capabilities across big pharma, biotech innovators, academic centers, and service providers determine competitive positioning

Corporate and institutional activity in the Dravet syndrome ecosystem reflects a mix of established pharmaceutical companies, specialty biotechs, academic centers, contract manufacturing organizations, and specialty pharmacies, each playing complementary roles. Established companies often drive late-stage development and large-scale manufacturing capacity, and they have the commercial infrastructure to support complex payer negotiations and broad distribution networks. Specialty biotechs contribute innovation through targeted mechanisms of action and novel formulations, frequently advancing therapies through earlier-phase trials and leveraging strategic partnerships to scale.

Academic medical centers and epilepsy clinics contribute critical real-world data, investigator-initiated studies, and natural history registries that inform both clinical development and health technology assessment. Contract manufacturing organizations and specialty pharmacies provide operational capabilities to manage orphan and pediatric product demands, including specialized compounding, cold chain logistics, and patient support services. Across this landscape, cross-sector collaboration is increasingly common, combining scientific expertise, clinical credibility, and distribution know-how to accelerate translation from bench to bedside. Companies that can integrate strong clinical evidence generation with sophisticated access strategies and robust patient support programs are positioned to lead in this therapeutic area.

Actionable, high-impact recommendations for product development, supply chain optimization, and payer engagement tailored to the unique demands of Dravet syndrome stakeholders

Industry leaders should pursue a set of pragmatic, evidence-focused actions to convert scientific advances into sustainable patient benefit and commercial success. First, prioritize early and continuous engagement with regulatory authorities and payers to align evidence generation with reimbursement requirements and to design adaptive development plans that accommodate pediatric safety and efficacy endpoints. Second, invest in diagnostic infrastructure and genetic testing partnerships to accelerate accurate early diagnosis, which in turn improves trial recruitment and real-world treatment targeting.

Third, reinforce supply chain resilience by diversifying sourcing of critical inputs, exploring nearshoring for selected manufacturing steps, and formalizing contingency plans to address tariff or trade disruptions. Fourth, develop differentiated distribution strategies that leverage specialty pharmacies for high-touch support, hospital pharmacies for acute care pathways, and online channels to reach geographically dispersed patient populations, with tailored adherence and education programs. Fifth, design age-appropriate formulations and administration routes that reflect the clinical realities of infants, children, adolescents, and adults, thereby enhancing tolerability and adherence. Finally, cultivate partnerships with specialty epilepsy centers and patient advocacy organizations to co-develop registries and real-world evidence initiatives that substantiate long-term outcomes and value, enabling more credible conversations with payers and health systems.

A transparent mixed-methods research methodology integrating clinical evidence review, expert interviews, and case study analysis to produce actionable and validated insights

The research methodology underpinning this analysis combines rigorous evidence synthesis with targeted stakeholder engagement to ensure relevance and credibility. Primary inputs include systematic review of peer-reviewed clinical literature, regulatory guidance documents, and clinical trial registries to capture therapeutic mechanisms, safety profiles, and trial designs. Secondary inputs draw on publicly available policy and payer documentation, technical white papers, and practice guidelines to contextualize access pathways and clinical adoption trends. Expert interviews with neurologists, epileptologists, specialty pharmacists, and health economics specialists were conducted to validate interpretive findings and to surface practical operational considerations not always explicit in the literature.

Qualitative thematic analysis and cross-validation of findings ensured consistency across data sources, while case study reviews of recent therapeutic launches provided real-world illustrations of commercialization challenges and successful strategies. The methodology emphasized transparency, with clear documentation of source types, interviewee roles, and analytical assumptions. Wherever possible, findings were triangulated across multiple sources to bolster reliability. This mixed-methods approach balances depth of clinical insight with practical commercial intelligence, providing stakeholders with actionable knowledge grounded in both evidence and frontline experience.

A forward-looking conclusion that synthesizes clinical progress, operational imperatives, and collaborative strategies necessary to improve care and access for Dravet syndrome patients

In conclusion, addressing the complex clinical and commercial challenges of Dravet syndrome requires coordinated efforts across diagnostic, therapeutic, and access domains. Advances in genetic diagnosis and diversifying therapeutic classes are creating new opportunities to improve seizure control and developmental trajectories, but realizing these benefits hinges on thoughtful evidence strategies, resilient supply chains, and payer-aligned value demonstration. Care delivery shifts toward telehealth and specialty-centric models offer avenues to expand access, yet disparities remain that demand targeted interventions at the regional and local levels.

Stakeholders who integrate precision diagnosis, age-appropriate formulation development, and robust patient support while engaging payers proactively will be best positioned to translate scientific progress into sustained clinical impact. Collaborative models that bring together industry, clinicians, and patient advocates to co-create registries and real-world evidence programs will strengthen the case for coverage and reimbursement. The path forward is pragmatic: combine scientific rigor with operational excellence and stakeholder alignment to deliver meaningful improvements for patients living with Dravet syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of gene therapy pipelines targeting SCN1A mutations in Dravet syndrome patients
  • 5.2. Increasing adoption of cannabidiol-based formulations for adjunctive seizure management in Dravet syndrome
  • 5.3. Rising investments in precision medicine initiatives for pediatric epileptic encephalopathies treatment
  • 5.4. Growing integration of real-world evidence to assess long-term treatment outcomes in Dravet syndrome
  • 5.5. Emergence of novel antisense oligonucleotides tailored to modulate defective sodium channel gene expression
  • 5.6. Development of at-home seizure monitoring devices leveraging AI for real-time intervention in Dravet syndrome
  • 5.7. Collaborations between pharmaceutical and biotech firms to accelerate clinical trials in rare epilepsy disorders

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dravet Syndrome Market, by Drug Class

  • 8.1. Cannabinoids
    • 8.1.1. Cbd
    • 8.1.2. Thc
  • 8.2. Gaba Modulators
    • 8.2.1. Clobazam
    • 8.2.2. Diazepam
    • 8.2.3. Stiripentol
  • 8.3. Sodium Channel Blockers
    • 8.3.1. Topiramate
    • 8.3.2. Valproate

9. Dravet Syndrome Market, by End User

  • 9.1. Home Care
  • 9.2. Hospital
  • 9.3. Specialty Epilepsy Centers

10. Dravet Syndrome Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Pharmacies

11. Dravet Syndrome Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Nasal
  • 11.3. Oral
  • 11.4. Oromucosal
  • 11.5. Transdermal

12. Dravet Syndrome Market, by Patient Age Group

  • 12.1. Adolescents
  • 12.2. Adults
  • 12.3. Children
  • 12.4. Infants

13. Dravet Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dravet Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dravet Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Jazz Pharmaceuticals plc
    • 16.3.2. UCB SA
    • 16.3.3. Marinus Pharmaceuticals, Inc.
    • 16.3.4. Stoke Therapeutics, Inc.
    • 16.3.5. Zogenix, Inc.
    • 16.3.6. Biogen Inc.
    • 16.3.7. Ionis Pharmaceuticals, Inc.
    • 16.3.8. Xenon Pharmaceuticals Inc.
    • 16.3.9. Ovid Therapeutics, Inc.
    • 16.3.10. Zynerba Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-202